SPP1 and myocardial infarction: Indeed, detrimental clinical outcomes have been observed in patients with acute coronary syndromes and elevated circulating levels of GDF-15 [16], syndecan-1, periostin, and osteopontin [17–19], while increased levels of syndecan-4 have been observed in patients with MI [20].